Clinical Efficacy and Safety of TPO in Combination with Eltrombopag in Patients with Solid Tumor Chemotherapy-Induced Thrombocytopenia

Aim: To evaluate the efficacy and safty of TPO in combination with eltrombopag in the treatment of solid tumor chemotherapy-induced thrombocytopenia (CIT).

Methods: 7 patients with thrombocytopenia after standard solid tumor chemotherapy were enrolled in this study, including gastric cancer(n=1), breast cancer(n=1), lung cancer(n=3) and liver cancer(n=2). They were treated with TPO (15000IU q.i.d.) in combination with eltrombopag (25mg t.i.d.) until the platelet count was recovered to 100 × 10⁹ / L or the medication time was up to 14 days. The time required for platelets to recover to > 50 × 10⁹ / L and ≥ 100 × 10⁹ / L, platelet transfusion times and adverse reactions were observed.

Results: After the treatment, the platelet counts of all patients were recovered to > 50 × 10⁹ / L, and 3 of them ≥ 100 × 10⁹ / L. The adverse reactions include muscle soreness(n=1), liver and kidney dysfunction(n=1), no case of them was above grade 3 according to WHO classification criteria for adverse reactions.

Conclusion: TPO in combination with eltrombopag is an effective and safe method for the treatment of solid tumor chemotherapy-induced thrombocytopenia (CIT).